Pritesh Shah, Chief Growth Officer at NovoCure Ltd (NVCR), sold 42,842 shares at $76.16 ($3.3M) on 2023-03-03, disclosed to the SEC on 2023-03-07.
Seasonal sale ($3.3M) by Chief Growth Officer — this insider has traded NVCR in March in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $76.16 | 1,570 | $120K | 3.7% |
| 2 | $76.16 | 1,570 | $120K | 3.7% |
| 3 | $76.16 | 2,942 | $224K | 6.9% |
| 4 | $76.16 | 2,942 | $224K | 6.9% |
| 5 | $76.16 | 16,909 | $1.3M | 39.5% |
| 6 | $76.16 | 16,909 |
| $1.3M |
| 39.5% |
| Total | $76.16 avg | 42,842 | $3.3M | 100% |
| Filing → |
| NVCR | SELL | 2023-03-06 | $141K | — | Filing → |
| NVCR | SELL | 2023-03-02 | $294K | — | Filing → |
| NVCR | SELL | 2023-01-09 | $42K | — | Filing → |